Postoperative Prognostic Factors in Lung Metastasis from Colorectal Cancer with Special Reference to Primary Lesion Features.

Aims and background Surgical resection remains the mainstay for the treatment of colorectal lung metastasis, but a group of patients who are medically inoperable or unsuitable for surgery are treated with radiotherapy. The purpose of this multi-institutional study was to evaluate the clinical outcome and investigate the prognostic factors affecting local control and survival in this subset of patients. Methods We retrospectively analyzed 30 patients with 43 lesions who underwent curative radiotherapy for isolated lung metastasis from colorectal cancer at nine institutions from 2003 and 2008. A total dose of 42–75 Gy at the peripheral planning target volume was administered in 3–35 fractions. The median biologically equivalent dose was 84 Gy (range, 58.5–180). Results Treatment response was complete in 10 (33.3%), partial in 13 (43.3%), stable in six (20.0%), and progressive in one patient (3.3%). The median follow-up period for all patients was 29.0 months (range, 5.0–93.8). Kaplan-Meier local control at 5 years was 44%. The median survival was 46.2 months, and the 5-year overall survival was 47%. Twenty-three patients (77%) experienced treatment failure, most of which were intrapulmonary failure. The intrapulmonary relapse-free survival and overall relapse-free survival at 5 years were 22% and 19%, respectively. Treatment response and pre-radiotherapy carcinoembryonic antigen level were significant prognostic factors for local control and survival. Grade 3–5 toxicity occurred in 7 patients. Three patients had grade 5 toxicity, including radiation pneumonitis, a tracheoesophageal fistula, and hemoptysis. Conclusions Curative radiotherapy for isolated lung metastasis from colorectal cancer in patients who are medially inoperable or unsuitable for surgery results in long-term survival, comparable to surgical resection. Curative radiotherapy could be an effective and noninvasive alternative if dose-limiting toxicity is carefully considered, particularly in patients with bilateral or central lesions.

Download Full-text

Predicting Survival Outcome of Patients With Colorectal Cancer and Only Lung Metastasis: A Population-Based Real-World Study

10.21203/rs.3.rs-80102/v1 ◽

2020 ◽

Author(s):

Hui Tang ◽

Jian-Feng Zhou ◽

Chun-Mei Bai

Keyword(s):

Colorectal Cancer ◽

Prognostic Factors ◽

Lung Metastasis ◽

Clinical Decision Making ◽

Histological Grade ◽

External Validation ◽

Roc Curves ◽

Survival Outcome ◽

Cancer Specific Survival ◽

Tumor Deposit

Abstract Background: Patients with metastatic colorectal cancer (mCRC) have a poor prognosis, but lung metastasis (LM) generally has a relatively desirable survival outcome. However, clinicians have had few tools for estimating the probability of survival in patients with colorectal cancer (CRC) and only LM (OLM). The present study aimed to develop nomograms estimating survival probability for patients with CRC and OLM.Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database of patients with CRC between 2010 and 2014 were retrieved for retrospective analysis. Patients with OLM diagnosed between 2010 and 2014, except for 2012 (n = 1,118) were used to conduct multivariate Cox analysis to identify independent prognostic factors. Nomograms estimating 1- and 3-year overall survival (OS) and cancer-specific survival (CSS) were developed. The nomograms were internally validated for concordance index (C-index), calibration plots, receiver operating characteristic (ROC) curves, and were also externally validated with independent patients diagnosed in 2012 (n = 261).Results: Age, marital status, tumor location, tumor size, T and N stage, CEA, tumor deposit, histological grade, primary or metastatic tumor surgery, chemotherapy, radiotherapy, and income were found to be independently associated with OS and/or CSS. The nomograms were constructed based on these prognostic factors. The C-index were high in internal validation (0.736 for OS and 0.741 for CSS) and external validation (0.656 for OS and 0.663 for CSS). Internal and external calibration plots and ROC curves demonstrated a good agreement between actual observation and nomogram prediction.Conclusions: The nomograms individually predict OS and CSS of patients with CRC and OLM and could aid in the personalized prognostic evaluation and clinical decision-making.

Download Full-text

Clinicopathologic Study on Liver Metastasis of Colorectal Cancer. With Special Reference to Subserosal Venous Invasion of Primary Lesion and Liver Metastasis.

Nippon Daicho Komonbyo Gakkai Zasshi ◽

10.3862/jcoloproctology.44.1005 ◽

1991 ◽

Vol 44 (7) ◽

pp. 1005-1018 ◽

Cited By ~ 2

Author(s):

S. Shirai

Keyword(s):

Colorectal Cancer ◽

Liver Metastasis ◽

Special Reference ◽

Venous Invasion ◽

Primary Lesion ◽

Clinicopathologic Study

Download Full-text

Prognosis Prediction for Stage II Colorectal Cancer by Fusing CT Radiomics and Deep Learning Features of Primary Lesion and Peripheral Lymph Nodes

SSRN Electronic Journal ◽

10.2139/ssrn.3736713 ◽

2020 ◽

Author(s):

Menglei Li ◽

Jing Gong ◽

Yichao Bao ◽

Dan Huang ◽

Junjie Peng ◽

...

Keyword(s):

Colorectal Cancer ◽

Deep Learning ◽

Lymph Nodes ◽

Primary Lesion ◽

Stage Ii ◽

Prognosis Prediction ◽

Peripheral Lymph ◽

Stage Ii Colorectal Cancer ◽

Deep Learning Features

Download Full-text

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

Open Medicine ◽

10.1515/med-2021-0215 ◽

2021 ◽

Vol 16 (1) ◽

pp. 169-174

Author(s):

Lei Lei ◽

Liu Yang ◽

Yang-yang Xu ◽

Hua-fei Chen ◽

Ping Zhan ◽

...

Keyword(s):

Prognostic Factors ◽

Clinical Features ◽

Survival Benefit ◽

Stage Iv ◽

Primary Lesion ◽

Hepatoid Adenocarcinoma ◽

Seer Database ◽

Primary Tumor Size ◽

Adenocarcinoma Of The Lung ◽

To Receive

Abstract Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann–Whitney U test was used for continuous variables. The Kaplan–Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005–0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary tumor size and treatment in patients with HAL, which have not been reported before.

Download Full-text

Role of Thermal Ablation in Colorectal Cancer Lung Metastases

Cancers ◽

10.3390/cancers13040908 ◽

2021 ◽

Vol 13 (4) ◽

pp. 908

Author(s):

Alexandre Delpla ◽

Thierry de Baere ◽

Eloi Varin ◽

Frederic Deschamps ◽

Charles Roux ◽

...

Keyword(s):

Colorectal Cancer ◽

Prognostic Factors ◽

Thermal Ablation ◽

Medical Oncology ◽

Pulmonary Metastases ◽

Lung Metastases ◽

Stereotactic Ablative Radiotherapy ◽

Chest Drainage ◽

Results Of Surgery

Background: Consensus guidelines of the European Society for Medical Oncology (ESMO) (2016) provided recommendations for the management of lung metastases. Thermal ablation appears as a tool in the management of these secondary pulmonary lesions, in the same manner as surgical resection or stereotactic ablative radiotherapy (SABR). Methods: Indications, technical considerations, oncological outcomes such as survival (OS) or local control (LC), prognostic factors and complications of thermal ablation in colorectal cancer lung metastases were reviewed and put into perspective with results of surgery and SABR. Results: LC rates varied from 62 to 91%, with size of the metastasis (<2 cm), proximity to the bronchi or vessels, and size of ablation margins (>5 mm) as predictive factors of LC. Median OS varied between 33 and 68 months. Pulmonary free disease interval <12 months, positive carcinoembryonic antigen, absence of neoadjuvant chemotherapy and uncontrolled extra-pulmonary metastases were poor prognostic factors for OS. While chest drainage for less than 48 h was required in 13 to 47% of treatments, major complications were rare. Conclusions: Thermal ablation of a selected subpopulation of patients with colorectal cancer lung metastases is safe and can provide excellent LC and delay systemic chemotherapy.

Download Full-text

Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study

BMC Gastroenterology ◽

10.1186/s12876-021-01791-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Hiroyuki Hisada ◽

Yu Takahashi ◽

Manabu Kubota ◽

Haruhisa Shimura ◽

Ei Itobayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Prognostic Factors ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Carcinoembryonic Antigen ◽

Prognostic Nutritional Index ◽

Hazard Ratio ◽

Elderly Group ◽

Younger Patients ◽

Nutritional Index

Abstract Background Colorectal cancer (CRC) is one of the most common cancers in the world. The number of elderly patients with CRC increases due to aging of the population. There are few studies that examined chemotherapy and prognostic factors in metastatic colorectal cancer (mCRC) patients aged ≥ 80 years. We assessed the efficacy of chemotherapy and prognostic factors among patients with mCRC aged ≥ 80 years. Methods We retrospectively analyzed clinical and laboratory findings of 987 patients newly diagnosed with CRC at Asahi General Hospital (Chiba, Japan) between January 2012 and December 2016. The Kaplan–Meier method was used for the overall survival (OS) and the log-rank test was used to identify difference between patients. A multivariate Cox proportional hazard regression analysis was performed to determine the hazard ratios and 95% confidence intervals (CIs) of prognostic factors among super-elderly patients. Results In total, 260 patients were diagnosed with mCRC (super-elderly group: n = 43, aged ≥ 80 years and younger group, n = 217, aged < 80 years). The performance status and nutritional status were worse in the super-elderly group than in the younger group. The OS of super-elderly patients who received chemotherapy was worse than that of younger patients (18.5 vs. 28.8 months; P = 0.052), although the difference was not significant. The OS of patients who received chemotherapy tended to be longer than that of those who did not; however, there were no significant differences in OS in the super-elderly group (18.5 vs. 8.4 months P = 0.33). Multivariate analysis revealed that carcinoembryonic antigen levels ≥ 5 ng/mL (hazard ratio: 2.27; 95% CI 1.09–4.74; P = 0.03) and prognostic nutritional index ≤ 35 (hazard ratio: 8.57; 95% CI 2.63–27.9; P = 0.0003) were independently associated with poor OS in the super-elderly group. Conclusions Patients with mCRC aged ≥ 80 years had lower OS than younger patients even though they received chemotherapy. Carcinoembryonic antigen and prognostic nutritional index were independent prognostic factors in super-elderly patients with mCRC, but chemotherapy was not. Trial registration: retrospectively registered.

Download Full-text